Fig. 3: Sotorasib and fulzerasib reduce MIG6 expression in mutant-KRAS G12C cell lines. | Cell Death Discovery

Fig. 3: Sotorasib and fulzerasib reduce MIG6 expression in mutant-KRAS G12C cell lines.

From: Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells

Fig. 3: Sotorasib and fulzerasib reduce MIG6 expression in mutant-KRAS G12C cell lines.The alternative text for this image may have been generated using AI.

Cells were treated with fulzerasib, sotorasib, cetuximab and sotorasib/fulzerasib combined with cetuximab. Fulz, fulzerasib, 0.005 µM for H358 and 2.5 µM for H23 and H2030. Soto, sotorasib, 0.005 µM for H358 and 5 µM for H23 and H2030. Cetuximab was tested in all cases at 50 µg/mL. Loading control Hsp90 corresponds to bands of Fig. 2. The intensity of the bands was first normalized using Hsp90, and then normalized to the basal condition (timepoint 0). Bands were quantified using ImageJ software.

Back to article page